Literature DB >> 25339368

microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7.

Zhi-Kang Cai1, Qi Chen1, Yan-Bo Chen1, Meng Gu1, Da-Chao Zheng1, Juan Zhou1, Zhong Wang1.   

Abstract

Micro (mi)RNAs are a group of small non-coding RNA molecules that have been demonstrated to regulate the expression of genes involved in tumorigenesis. The relevance of microRNAs in the development, progression and prognosis of prostate cancer is not fully understood. miR-155 has been implicated in the induction of breast, lung and liver cancer, but its role in prostate cancer has not been investigated. In the present study, the biological function of miR-155 was investigated in prostate cancer for the first time, to the best of our knowledge. It was demonstrated that the expression of miR-155 was upregulated in prostate cancer tissues and cell lines as determined by quantitative reverse transcription-polymerase chain reaction. Furthermore, overexpression of miR-155 promoted cell proliferation, as indicated by MTT assay. Flow cytometric analysis demonstrated that inhibition of miR-155 induced cell cycle arrest and promoted apoptosis in prostate cancer cells. In addition, western blot analysis indicated that annexin (ANX)7 was significantly downregulated in prostate cancer tissues and cells. A luciferase reporter assay indicated that ANX7 was a target of miR-155, which suggested that miRNA-155 promoted the proliferation of prostate cancer cells by regulating ANX7 expression levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339368     DOI: 10.3892/mmr.2014.2744

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  21 in total

Review 1.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

2.  Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A.

Authors:  Wanjun Li; Guoyin Li; Zhigang Fan; Tao Liu
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

3.  Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells.

Authors:  Lixia Lv; Xiumei An; Hongyan Li; Lanxiu Ma
Journal:  Oncol Lett       Date:  2015-12-03       Impact factor: 2.967

Review 4.  Non-viral based miR delivery and recent developments.

Authors:  Annalise Elizabeth Labatut; George Mattheolabakis
Journal:  Eur J Pharm Biopharm       Date:  2018-04-19       Impact factor: 5.571

5.  Prognostic value of TERF1 expression in prostate cancer.

Authors:  Gabriel Arantes Dos Santos; Nayara Izabel Viana; Ruan Pimenta; Vanessa Ribeiro Guimarães; Juliana Alves de Camargo; Poliana Romão; Sabrina T Reis; Katia Ramos Moreira Leite; Miguel Srougi
Journal:  J Egypt Natl Canc Inst       Date:  2021-09-06

Review 6.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

7.  MiR-300 regulate the malignancy of breast cancer by targeting p53.

Authors:  Xiao-Heng Xu; Da-Wei Li; Hui Feng; Hong-Mei Chen; Yan-Qiu Song
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells.

Authors:  X-H He; W Zhu; P Yuan; S Jiang; D Li; H-W Zhang; M-F Liu
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

Review 9.  The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.

Authors:  Zuhair Hawa; Inamul Haque; Arnab Ghosh; Snigdha Banerjee; LaCoiya Harris; Sushanta K Banerjee
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

Review 10.  Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.

Authors:  Alessandra Bosutti; Fabrizio Zanconati; Gabriele Grassi; Barbara Dapas; Sabina Passamonti; Bruna Scaggiante
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.